Vertigo Drugs: What Causes It, What Treats It, and When to Call a Doctor

What Is Vertigo and Why Does It Happen?

Vertigo is not dizziness in a vague sense. It is the specific illusion that you or your surroundings are rotating, tilting, or swaying, produced when the brain receives conflicting positional signals from the inner ear, eyes, or sensory nerves. The peripheral vestibular system, primarily the semicircular canals and otolith organs inside the labyrinth, generates the majority of clinical cases.

Peripheral Versus Central Origins

Peripheral vertigo originates inside the inner ear or along cranial nerve VIII. It accounts for the overwhelming majority of presentations in primary care. BPPV, vestibular neuritis, and Meniere disease together explain most peripheral cases. Symptoms tend to be intense but brief, often worsened by head movement, and accompanied by nausea without serious neurological signs.

Central vertigo originates in the brainstem or cerebellum. It is less common but far more dangerous. A 2014 analysis published in Annals of Emergency Medicine found that roughly 3.2% of patients presenting to the ED with an isolated dizziness complaint had a posterior-circulation stroke or TIA, a figure high enough that every new-onset vertigo presentation deserves a careful neurological screen [1].

The Inner-Ear Mechanics Behind BPPV

In BPPV, calcium-carbonate crystals called otoconia detach from the utricle and migrate into one of the semicircular canals, most often the posterior canal. Each head movement sweeps these crystals through endolymph, generating a false rotational signal that lasts seconds to about one minute before dissipating. The Dix-Hallpike test reproduces this with characteristic upbeat-torsional nystagmus and a latency of 5-20 seconds [2].

Drugs That Cause Vertigo

Many patients and clinicians overlook iatrogenic vertigo. A thorough medication review should precede imaging or specialist referral in any new vertigo case.

Aminoglycosides and Ototoxic Antibiotics

Aminoglycoside antibiotics, including gentamicin, tobramycin, and streptomycin, destroy type I hair cells in the vestibular neuroepithelium through free-radical oxidative stress. Vestibulotoxicity can be permanent and dose-dependent. A prospective study of 90 patients receiving IV gentamicin for endocarditis found that 9 of 90 (10%) developed measurable vestibular dysfunction by electronystagmography within two weeks of starting therapy [3]. Intratympanic gentamicin is also intentionally used as a chemical labyrinthectomy for refractory Meniere disease, which underscores the drug's potency on hair cells.

Loop Diuretics

Furosemide and ethacrynic acid alter endolymph ionic composition by inhibiting the Na-K-2Cl cotransporter in the stria vascularis. High-dose IV furosemide, particularly above 1 mg/kg/hour, carries the greatest risk. The combination of a loop diuretic with an aminoglycoside multiplies ototoxic risk substantially [4].

Antiepileptic Drugs

Carbamazepine, phenytoin, and valproate all list vertigo or dizziness as dose-related adverse effects. Carbamazepine produces nystagmus and vertigo at serum levels exceeding 10 mcg/mL. Phenytoin toxicity above 25 mcg/mL classically produces gaze-evoked nystagmus and ataxic vertigo. Drug level monitoring reduces the incidence of these effects.

Antihypertensives and Vestibular Perfusion

Beta-blockers, calcium-channel blockers, and alpha-1 antagonists can all produce orthostatic hypotension sufficient to trigger presyncope that patients describe as vertigo. This is technically a perfusion problem rather than a vestibular one, but the subjective experience overlaps enough that medication timing relative to symptoms is a key diagnostic clue.

Antidepressants and Antipsychotics

SSRIs and SNRIs produce transient dizziness and vestibular symptoms during initiation and, notably, on abrupt discontinuation (so-called SSRI discontinuation syndrome). Quetiapine and other second-generation antipsychotics carry vertigo rates of 3-10% in prescribing-information adverse-event tables, largely through orthostatic mechanisms.

Salicylates and NSAIDs

High-dose aspirin, above 6 g/day in adults, reliably produces tinnitus and vertigo through reversible cochlear effects. Standard analgesic or antiplatelet doses do not carry this risk.

Drug-Induced Vertigo: A Clinician's Screening Framework

When a patient presents with new vertigo, run through four questions in order:

1. Did symptoms start or worsen within two weeks of a new prescription or dose change?
2. Is the patient taking any aminoglycoside, loop diuretic, antiepileptic, or antihypertensive?
3. Do symptoms improve on days the patient misses a dose?
4. Does the Dix-Hallpike reproduce the vertigo, or does head position make no difference?

A "yes" to questions 1-3 and a "no" to question 4 strongly suggests drug-induced vestibular disruption rather than BPPV, and dose adjustment or substitution should precede further workup.

Drugs That Treat Vertigo

Vestibular Suppressants for Acute Episodes

Meclizine (Antivert)

Meclizine is an H1-antihistamine with anticholinergic properties that suppress central vestibular nuclei activity. The FDA approved it specifically for vertigo management. Standard dosing is 25-50 mg orally every 6-8 hours during acute episodes. A randomized controlled trial in 100 patients with acute vestibular neuritis found meclizine equally effective to diazepam for short-term symptom control, with a more favorable sedation profile [5]. Because vestibular suppressants can slow central compensation, clinicians typically limit use to the first 72 hours of an acute attack rather than prescribing for weeks.

Dimenhydrinate (Dramamine)

Dimenhydrinate is a salt of diphenhydramine and 8-chlorotheophylline. It shares meclizine's H1-antihistamine mechanism and is widely available over the counter at 50-100 mg every 4-6 hours. Evidence for its use in acute peripheral vertigo is largely observational, but it is endorsed in guidelines from the American Academy of Otolaryngology for short-term symptomatic relief [6].

Promethazine

Promethazine 12.5-25 mg every 6 hours, oral or rectal, adds a dopamine-D2 blocking action to antihistamine suppression. It is especially useful when nausea dominates the clinical picture. Its sedative burden is high, and it carries an FDA black-box warning for use in children under two years of age.

Benzodiazepines

Diazepam 2-5 mg orally or lorazepam 1-2 mg sublingually suppresses vestibular nuclei through GABA-A potentiation. Both are effective but carry risks of dependence, respiratory depression, and cognitive impairment, particularly in older adults. A 2019 American Geriatrics Society Beers Criteria update lists benzodiazepines as potentially inappropriate in adults 65 and older, which covers a large share of the BPPV-affected population [7]. Reserve them for severe acute episodes when antihistamines have failed.

Betahistine for Meniere Disease

Betahistine is a histamine H3-receptor antagonist with weak H1-agonist activity. Its proposed mechanism is improved endolymphatic pressure regulation through enhanced microcirculation in the stria vascularis. A Cochrane systematic review (17 trials, 1,025 patients) concluded that betahistine likely reduces the frequency of vertigo attacks in Meniere disease compared to placebo, though the certainty of evidence was rated moderate due to heterogeneous outcome definitions across trials [8]. Standard dosing is betahistine 16 mg three times daily or 24 mg twice daily; the 48 mg/day total dose appears to perform better than lower doses in subgroup analyses.

Betahistine is not FDA-approved in the United States but is prescribed off-label and is approved in more than 100 other countries.

Intratympanic Dexamethasone and Gentamicin

For Meniere disease refractory to oral therapy, two intratympanic (IT) injections have evidence:

IT dexamethasone: A double-blind RCT by Garduno-Anaya et al. (N=22) found that 4 mg/mL dexamethasone injected twice weekly for four weeks reduced vertiginous attacks by 82% versus 57% for saline at 24 months, with no hearing change in the treatment group [9].

IT gentamicin: Achieves vertigo control in 80-90% of unilateral Meniere cases at the cost of some ipsilateral hearing loss in roughly 25% of patients depending on dosing protocol. The single low-dose protocol (one injection, then titrate) minimizes hearing risk versus fixed multi-injection schedules [10].

Scopolamine (Transdermal)

Scopolamine 1.5 mg transdermal patch, applied behind the ear every 72 hours, blocks muscarinic receptors in the vestibular nucleus and vomiting center. It performs well for motion-sickness-related vertigo. An RCT of 1,025 naval personnel demonstrated scopolamine reduced motion sickness severity scores by 42% compared to placebo [11]. Anticholinergic side effects, including dry mouth, blurred vision, and urinary hesitancy, limit its use in older adults.

Steroids for Vestibular Neuritis

Prednisone 60 mg/day tapered over 21 days is the standard regimen for vestibular neuritis when begun within 72 hours of symptom onset. A randomized trial by Strupp et al. Published in The New England Journal of Medicine (N=141) found that methylprednisolone significantly improved vestibular function recovery at 12 months compared to placebo or valacyclovir alone (39.4% complete recovery versus 25.7% placebo, P<0.05) [12]. Valacyclovir did not add benefit beyond placebo in that trial, making antiviral use in isolated vestibular neuritis unsupported.

Non-Drug Treatments: Why Maneuvers Come First for BPPV

BPPV does not need a vestibular suppressant. It needs physics.

The Epley Maneuver

The Epley canalith-repositioning procedure guides detached otoconia back into the utricle through a four-position head-movement sequence. A Cochrane review (11 trials, 745 participants) found the Epley maneuver was significantly more effective than sham maneuver for posterior-canal BPPV, with symptom resolution in roughly 80% of patients after one or two sessions versus 10-20% in controls [13]. The procedure takes under five minutes in a clinic.

Prescribing meclizine for BPPV without attempting repositioning first delays recovery and adds unnecessary drug exposure. The American Academy of Neurology 2008 guideline, reaffirmed in subsequent updates, explicitly states that the Epley maneuver is safe, effective, and should be offered before pharmacotherapy in posterior-canal BPPV [14].

Vestibular Rehabilitation Therapy

For persistent dizziness after the acute phase of vestibular neuritis or incomplete resolution of BPPV, vestibular rehabilitation therapy (VRT) delivered by a trained physical therapist accelerates central compensation. A meta-analysis of 27 RCTs (N=1,668) found VRT produced clinically meaningful improvements in dizziness handicap and dynamic gait compared to control at 4-12 weeks [15].

How Vertigo Is Diagnosed

Diagnosis depends heavily on history and physical examination, not neuroimaging. Three questions guide most cases:

1. Is the sensation truly rotational (vertigo) or non-rotational lightheadedness?
2. Is it episodic or constant?
3. Is it provoked by head position changes or spontaneous?

Bedside Examination Tools

The Dix-Hallpike test differentiates posterior-canal BPPV from other causes with a sensitivity of roughly 79% and specificity of 75% when performed correctly [2].

HINTS exam (Head-Impulse, Nystagmus type, Test of Skew) distinguishes central from peripheral vertigo at the bedside in patients with acute continuous vertigo. In a prospective study by Kattah et al. (N=101 patients with acute vestibular syndrome), HINTS outperformed early MRI for detecting posterior-circulation stroke, with a sensitivity of 100% and specificity of 96% when performed by trained clinicians [16].

Pure-tone audiometry is indicated when hearing loss accompanies vertigo, as this pattern narrows the differential toward Meniere disease, labyrinthitis, or acoustic neuroma.

When Imaging Is Needed

MRI with gadolinium and diffusion-weighted imaging (DWI) is the study of choice when central vertigo is suspected. CT adds little in posterior-fossa evaluation due to bone artifact. MRI should be ordered same-day in any patient with:

• New focal neurological deficits
• Severe occipital headache of sudden onset
• Inability to stand or walk (ataxia out of proportion to the dizziness)
• Risk factors for posterior-circulation stroke including hypertension, diabetes, or atrial fibrillation

When Should I Worry About Vertigo?

Most vertigo is benign and resolves. The following presentations are exceptions that require urgent evaluation, not watchful waiting.

Call 911 or go to an emergency department immediately if vertigo is accompanied by:

• Sudden severe headache unlike prior headaches
• Diplopia, dysarthria, or dysphagia
• New unilateral limb weakness or facial droop
• Loss of consciousness or near-syncope
• Ataxia severe enough to prevent standing without support

A posterior-fossa stroke can present with isolated vertigo for the first hours before other signs emerge. The 3.2% stroke prevalence figure in ED dizziness patients cited earlier [1] means a threshold for imaging must remain low when clinical context includes vascular risk factors.